- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04809181
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
February 19, 2023 updated by: Yi Luo, First Affiliated Hospital of Zhejiang University
Azacitidine in Combination With Venetoclax Treatment for Prevention of Relapse in MRD Positive Post Allogeneic Hematopoietic Stem Cell Transplantation Acute Myelogenous Leukemia/ Myelodysplastic Syndrome Patients
In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allogeneic hematopoietic stem cell transplantation for AML/MDS.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
The technology of Allogeneic Hematopoietic stem cell transplantation (allo-HSCT) has been continuously improved, relpase is still the leading cause of death after allo-HSCT.
Monitoring of micro residual disease (MRD) after allogeneic HSCT provides a risk stratification of relpase risk in patients after transplantation.There is an urgent need to find an effective intervention plan for patients with MRD positive after transplantation, in order to reduce the risk of relapse after transplantation and improve long-term survival.The combination of demethylated drugs with venetoclax has shown promising results in clinical trials in AML patients who cannot tolerate induction chemotherapy.In patients with MRD-positive patients after AML/MDS allo-HSCT, azacytidine combined with venetoclax may be effective in eliminating small residual diseases, reducing the risk of relapse, and ultimately improving long-term survival.The primary purpose of this study was to explore an effective protocol to reduce the risk of relapse in patients with MRD positive after allo-HSCT for AML/MDS.
Study Type
Interventional
Enrollment (Anticipated)
95
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- The First Affiliated Hospital of Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients between 18 years old and 65 years old.
- Patients with AML or MDS diagnosed according to WHO diagnostic criteria.
- Patients who received allogeneic hematopoietic stem cell transplantation and achieved complete remission.
- MRD was positive after transplantation, MFC > 0.1% and / or fusion gene and gene mutation (WT1 > 0.6%, AML1-ETO > 0.4%, others >1%).
- ECOG body status score 0-2.
- Patients with expected survival time >=3 months.
- Good organ function level: ANC (neutrophil absolute value >=1.0x10^9/L; PLT >=30x10^9/L; HB >=80g/L; Tibil <=1.5 ULN; ALT / AST <=2.5 ULN; bun / Cr <=1.5 ULN; LVEF >=50%).
- Patients who have received any anti-tumor treatment (including radiotherapy, chemotherapy, surgery or molecular targeted treatment) for more than 4 weeks from the end of the previous treatment.
- Patients with no GVHD and no previous history of 3 or more degrees of aGVHD. 10. Patients who voluntarily participate in the clinical trial, understand the research procedure and can sign the informed consent in writing.
Exclusion Criteria:
- Patients with severe cardiac insufficiency and EF lower than 60%; or patients with severe arrhythmia who could not tolerate super pretreatment.
- Patients with activity of aGVHD or extensive cGVHD.
- Patients with BCR/ABL positive.
- Patients who were previously known to be resistant to azacytidine or dessicabine or venetoclax.
- In patients with severe pulmonary insufficiency (obstructive and / or restrictive ventilation disorders), the researchers evaluated the patients who could not tolerate the super pretreatment scheme.
- Patients with severe liver function impairment and liver function indexes (alt, TBIL) more than 3 ULN were evaluated as intolerant of super pretreatment.
- In patients with severe renal insufficiency, the renal function index (CR) is more than 2 times of the upper limit of the normal value (ULN), or the 24-hour creatinine clearance rate (CR) is less than 50ml / min, the researchers evaluated that they could not tolerate the super pretreatment scheme.
- In patients with severe active infection, the researchers evaluated that they could not tolerate the pretreatment.
- Patients who had allergic reactions or serious adverse reactions in the previous use of pretreatment related drugs could not be included in the study.
- Patients with hematological recurrence (bone marrow smear: proportion of primordial cells >=5%) or any extramedullary recurrence.
- Other reasons why the researchers could not be selected.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MRD positive AML/MDS patients after allogeneic hematopoietic stem cell transplantation
|
Azacitidine in combination with venetoclax
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
relapse-free survival
Time Frame: 2 year
|
relapse-free survival
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: 2 year
|
overall survival
|
2 year
|
graft-versus-host disease -free relapse-free survival
Time Frame: 2 year
|
graft-versus-host disease -free relapse-free survival
|
2 year
|
cumulative incidence of aGVHD
Time Frame: 100 days
|
cumulative incidence of aGVHD
|
100 days
|
cumulative incidence of cGVHD
Time Frame: 2 year
|
cumulative incidence of cGVHD
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2021
Primary Completion (Anticipated)
March 19, 2024
Study Completion (Anticipated)
March 19, 2026
Study Registration Dates
First Submitted
March 19, 2021
First Submitted That Met QC Criteria
March 19, 2021
First Posted (Actual)
March 22, 2021
Study Record Updates
Last Update Posted (Estimate)
February 21, 2023
Last Update Submitted That Met QC Criteria
February 19, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZJU-HSCT-AZA02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
Clinical Trials on Azacitidine in Combination With Venetoclax
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaboratorsRecruiting
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
ZePing ZhouGuizhou Provincial People's Hospital; Second Xiangya Hospital of Central South... and other collaboratorsRecruiting
-
Hematology department of the 920th hospitalRecruitingAcute Myeloid LeukemiaChina
-
The Second Affiliated Hospital of Kunming Medical...Not yet recruitingAcute Myeloid Leukemia | Decitabine | Venetoclax | Elderly AML Patients | Unfit, New-diagnosis AMLChina
-
Dalian Medical UniversityNot yet recruiting
-
The First Affiliated Hospital of Soochow UniversityThe Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaboratorsRecruiting
-
Centre Hospitalier Universitaire de NiceRecruitingAcute Myeloid LeukemiaFrance
-
The First Affiliated Hospital with Nanjing Medical...Huai'an First People's Hospital; Yancheng First People's Hospital; The Affiliated...RecruitingAcute Myeloid LeukemiaChina
-
The First Affiliated Hospital of Soochow UniversityRecruiting